Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Precision Therapeutics, Inc., a life science company that develops personalized medicine products for individualizing cancer care, today announced that a clinical study which demonstrates the feasibility of the ChemoFx® chemoresponse assay to identify patients unlikely to respond to first-line therapy has been accepted for presentation at the 2013 Annual Meeting of the Western Association of Gynecologic Oncologists (WAGO). The meeting will be held from June 27-29, 2013 at the W Seattle in Seattle, Washington.
Help employers find you! Check out all the jobs and post your resume.
Precision Therapeutics, Inc., a life science company that develops personalized medicine products for individualizing cancer care, today announced that a clinical study which demonstrates the feasibility of the ChemoFx® chemoresponse assay to identify patients unlikely to respond to first-line therapy has been accepted for presentation at the 2013 Annual Meeting of the Western Association of Gynecologic Oncologists (WAGO). The meeting will be held from June 27-29, 2013 at the W Seattle in Seattle, Washington.
Help employers find you! Check out all the jobs and post your resume.
